Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
P Tarantino, R Carmagnani Pestana… - CA: a cancer journal …, 2022 - Wiley Online Library
As distinct cancer biomarkers have been discovered in recent years, a need to reclassify
tumors by more than their histology has been proposed, and therapies are now tailored to …
tumors by more than their histology has been proposed, and therapies are now tailored to …
Unmet supportive care needs of people with advanced cancer and their caregivers: a systematic scoping review
Examining and addressing unmet care needs is integral to improving the provision and
quality of cancer services. This review explored the prevalence of unmet supportive care …
quality of cancer services. This review explored the prevalence of unmet supportive care …
Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer
Background Trastuzumab emtansine is the current standard treatment for patients with
human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose …
human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose …
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆
Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …
Overall survival with ribociclib plus letrozole in advanced breast cancer
GN Hortobagyi, SM Stemmer, HA Burris… - … England Journal of …, 2022 - Mass Medical Soc
Background In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole
resulted in significantly longer progression-free survival than letrozole alone among …
resulted in significantly longer progression-free survival than letrozole alone among …
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-
HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial …
HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial …
[HTML][HTML] Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
N Harbeck, P Rastogi, M Martin, SM Tolaney… - Annals of …, 2021 - Elsevier
Background Adjuvant abemaciclib combined with endocrine therapy (ET) previously
demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) …
demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) …
[HTML][HTML] First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival …
LA Emens, S Adams, CH Barrios, V Diéras, H Iwata… - Annals of …, 2021 - Elsevier
Background Guidelines recommend atezolizumab plus nab-paclitaxel (A+ nP) for first-line
treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer …
treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer …
Evolution of HER2-low expression from primary to recurrent breast cancer
F Miglietta, G Griguolo, M Bottosso, T Giarratano… - NPJ breast …, 2021 - nature.com
About a half of HER2-negative breast cancer (BC) show HER2-low expression that can be
targeted by new antibody-drug conjugates. The main aim of this study is to describe the …
targeted by new antibody-drug conjugates. The main aim of this study is to describe the …
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2 …
HS Rugo, F Lerebours, E Ciruelos, P Drullinsky… - The Lancet …, 2021 - thelancet.com
Summary Background Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant
showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced …
showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced …